Tag Archives: SpicyIP Strategy

Roche vs Cipla: Was Roche’s Legal Strategy Flawed?

by
15 Comments

Readers may recollect our earlier post on legal strategy in the context of the famous Novartis (Glivec) patent dispute. I compared the patent strategies of Roche and Novartis and noted: “Compare and contrast Novartis’ aggressive and weakly thought out patent strategy with that of Roche, which has gone on to acquire four patents already. Its patent covering pegylated interferon (Pegasus) has now been challenged in a post grant opposition, but one hardly hears of this in the press. Roche has…


Read More »

Glivec / Gleevec (Imatinib) – Novartis’ many crystalline forms

by
Leave a Comment

I posted a note earlier in Spicy IP Tidbits about Novartis’ alpha crystalline Glivec (imatinib) patent which has recently come to light. This application was filed back in 2004, before the changes to Indian patent law, and the subsequent (and ongoing) fight with the IPAB, etc.(Click here for a list of earlier posts about Novartis and Glivec on SpicyIP.) For those who aren’t aware, Novartis has other patents covering imatinib in similar ways. Take for example, WO 2007023182 for Delta…


Read More »

Indian Ingenuity in the Pharma industry – not just generics

by
8 Comments

Eli Lilly and Glenmark announced last week a deal in which Lilly will license from Glenmark the rights to a new set of molecules (a portfolio of TRPV1 antagonist molecules, including a clinical compound, GRC 6211.) The world has for some time been well aware (and impressed) with the performance of India’s top ‘generic’ companies. In an interesting example of taking a generic IP Strategy to the next level, Lupin entered into two recent IP portfolio sales to Servier earlier…


Read More »

Big Mac’s new India strategy – what about IP?

by
Leave a Comment

The Economic Times recently reported on McDonalds’ recent redirection away from children and towards teenagers, adults and even the elderly. This calls for a major reassessment of the branding and IP Strategy. We’re all aware of the relatively recent “I’m lovin it” brand – but what else could McDonalds do from an IP perspective to make the most of the refocus? Interestingly, the refocus hasn’t yet hit McDonads’ India website yet – when I recently looked at it, Ronald McDonald…


Read More »

Indian Pharmaceutical Lifecycle Management – an oxymoron?

by
2 Comments

India’s section 3(d) poses some interesting problems for innovator companies seeking to get the best return on investment in India (read ‘longest period of monopoly’). Is that the end of the story for Lifecycle Management in India, though? First up – for those who think that “Lifecycle Management” is a dirty word (phrase), consider (a) the number of ‘innovators’ with generic subsidiaries, or who have entered authorised generic deals, and (b) the enormous and successful new chemical entity programs by…


Read More »